Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: a case report.

ABSTRACT:

Background

For patients with metastatic upper tract urothelial carcinoma (UTUC), the preferred first-line treatment is platinum-based chemotherapy. Immunotherapy can be considered a subsequent treatment if the chemotherapy is ineffective or the disease progresses. However, how should treatment be administered if immunotherapy is useless and the patient cannot take chemotherapy? Especially in patients who have metastasized after radical nephroureterectomy (RNU).

Case presentation

A 68-year-old woman was admitted to the hospital due to left flank pain for two weeks and was diagnosed with metastatic UTUC after RNU. The patient underwent systemic chemotherapy with gemcitabine and cisplatin (GC), as well as reduced-dose GC, but developed myelosuppression. Immunotherapy was ineffe

SUBMITTER: Li W 

PROVIDER: S-EPMC11427362 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature